Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,570 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Longitudinal imaging of therapeutic enzyme expression after gene therapy for Fabry disease using positron emission tomography and the radiotracer [18F]AGAL.
Kaittanis C, Teceno T, Knight A, Petibon Y, Sandoval P, Cohen L, Ahn SH, Belanger AP, Clark LM, Nguyen QD, Ruangsiriluk W, Mukherji S, Constantinescu CC, Amenta AL, Narayanan S, Deshpande M, Islam R, Yuan S, McQuade P, Winkelmann CT, Lohith TG. Kaittanis C, et al. Among authors: knight a. Mol Ther. 2024 Nov 19:S1525-0016(24)00748-2. doi: 10.1016/j.ymthe.2024.11.021. Online ahead of print. Mol Ther. 2024. PMID: 39563031 Free article.
Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
Patel S, Knight A, Krause S, Teceno T, Tresse C, Li S, Cai Z, Gouasmat A, Carroll VM, Barret O, Gottmukkala V, Zhang W, Xiang X, Morley T, Huang Y, Passchier J. Patel S, et al. Among authors: knight a. Mol Imaging Biol. 2020 Aug;22(4):832-841. doi: 10.1007/s11307-019-01428-0. Mol Imaging Biol. 2020. PMID: 31728839
Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery.
Bernard-Gauthier V, Mossine AV, Knight A, Patnaik D, Zhao WN, Cheng C, Krishnan HS, Xuan LL, Chindavong PS, Reis SA, Chen JM, Shao X, Stauff J, Arteaga J, Sherman P, Salem N, Bonsall D, Amaral B, Varlow C, Wells L, Martarello L, Patel S, Liang SH, Kurumbail RG, Haggarty SJ, Scott PJH, Vasdev N. Bernard-Gauthier V, et al. Among authors: knight a. J Med Chem. 2019 Nov 14;62(21):9600-9617. doi: 10.1021/acs.jmedchem.9b01030. Epub 2019 Oct 21. J Med Chem. 2019. PMID: 31535859 Free PMC article.
Radiosynthesis, In Vitro and In Vivo Evaluation of [18F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies.
Lindberg A, Knight AC, Sohn D, Rakos L, Tong J, Radelet A, Mason NS, Stehouwer JS, Lopresti BJ, Klunk WE, Sandell J, Sandberg A, Hammarström P, Svensson S, Mathis CA, Vasdev N. Lindberg A, et al. Among authors: knight ac. ACS Chem Neurosci. 2021 Feb 17;12(4):596-602. doi: 10.1021/acschemneuro.0c00801. Epub 2021 Jan 26. ACS Chem Neurosci. 2021. PMID: 33497190 Free PMC article.
In Vitro Evaluation of [3H]CPPC as a Tool Radioligand for CSF-1R.
Knight AC, Varlow C, Zi T, Liang SH, Josephson L, Schmidt K, Patel S, Vasdev N. Knight AC, et al. ACS Chem Neurosci. 2021 Mar 17;12(6):998-1006. doi: 10.1021/acschemneuro.0c00802. Epub 2021 Mar 5. ACS Chem Neurosci. 2021. PMID: 33667059 Free PMC article.
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial.
Bryan RT, Liu W, Pirrie SJ, Amir R, Gallagher J, Hughes AI, Jefferson KP, Knight A, Nanton V, Mintz HP, Pope AM, Cherian J, Ekwueme K, Gommersall L, Hellawell G, Hunter-Campbell P, Kanda Swamy G, Kotwal S, Kumar V, Mak D, Mohee A, Nambirajan T, Ward DG, Kennish SJ, Catto JWF, Patel P, James ND; BladderPath Collaborative Group. Bryan RT, et al. Among authors: knight a. J Clin Oncol. 2025 Jan 14:JCO2302398. doi: 10.1200/JCO.23.02398. Online ahead of print. J Clin Oncol. 2025. PMID: 39808757
Implementation of a data-driven quality improvement program in primary care for patients with coronary heart disease: a mixed methods evaluation of acceptability, satisfaction, barriers and enablers.
Hafiz N, Hyun K, Tu Q, Knight A, Chow CK, Hespe C, Briffa T, Gallagher R, Reid CM, Hare DL, Zwar N, Woodward M, Jan S, Atkins ER, Laba TL, Halcomb E, Johnson T, Manandi D, Usherwood T, Redfern J. Hafiz N, et al. Among authors: knight a. Aust J Prim Health. 2025 Jan;31:PY24034. doi: 10.1071/PY24034. Aust J Prim Health. 2025. PMID: 39808521
Molecular Determinants of Protein Pathogenicity at the Single-Aggregate Level.
Urbanek A, Garland EF, Prescott EE, King MC, Olerinyova A, Wareing HE, Georgieva N, Bradshaw EL, Tzokov SB, Knight A, Tartakovskii AI, Malm T, Highley JR, De S. Urbanek A, et al. Among authors: knight a. Adv Sci (Weinh). 2025 Jan 13:e2410229. doi: 10.1002/advs.202410229. Online ahead of print. Adv Sci (Weinh). 2025. PMID: 39804980
1,570 results